N-t-butyl-N-methylacetamide | 24331-69-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-t-butyl-N-methylacetamide
• 英文别名: N-tert-butyl-N-methylacetamide；N-t-Butyl-N-methylacetamid；N-tert.-Butyl-N-methylacetamid；N-Methyl-N-tert.-butyl-acetamid
• CAS: 24331-69-9
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: DRBCZXVTHBKPCG-UHFFFAOYSA-N

物化性质

• 沸点：
  179.7±8.0 °C(Predicted)
• 密度：
  0.870±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二叔丁基过氧化物 、 N-t-butyl-N-methylacetamide 在 iron(III) chloride 作用下， 以 1,2-二氯-2-甲基丙烷 为溶剂， 反应 24.0h， 以62%的产率得到N-(tert-butoxymethyl)-N-(tert-butyl)acetamide
  参考文献：
  名称：

  Iron-Catalyzed Oxidative Coupling of Alkylamides with Arenes through Oxidation of Alkylamides Followed by Friedel−Crafts Alkylation

  摘要：

  FeCL(3) in combination with t-BuOOt-Bu as an oxidant was found to be an efficient catalyst for oxidation of alkylamides to alpha-(tert-butoxy)alkylamides. FeCl(2) and CuCl showed, respectively, almost the same and slightly lower activities compared with FeCl(3) in the tert-butoxylation of N-phenylpyrrolidone (1a), whereas no tert-butoxylated product was obtained by use of Fe(OTf)(3), RuCl(3), or Zr(OTf)(4). FeCl(3) was found to be effective also as a catalyst for the Friedel-Crafts alkylation with thus obtained alpha-(tert-butoxy)alkylamides. The Friedel-Crafts alkylation proceeded smoothly also in the presence of a catalytic amount of Fe(OTf)(3), RuCl(3), or Zr(OTf)(4). In contrast, FeCl(2) and CuCl, which showed certain activity toward the tert-butoxylation, failed to promote the Friedel Crafts alkylation. Among the transition metal complexes thus far examined, only FeCl(3) showed high catalytic activities for both the oxidation and the Friedel-Crafts alkylation. The bifunctionality of FeCl(3) was utilized for the oxidative coupling of alkylamides with arenes through a tandem reaction consisting of oxidation of alkylamides to alpha-(tert-butoxy)alkylamides and the following Friedel-Crafts alkylation. The FeCl(3)-catalyzed oxidative coupling is applicable to a wide variety of alkylamides and arenes, though a combination of FeCl(3) with Fe(OTf)(3) was found to be effective for the reaction of arenes with low nucleophilicity. A Fe(II)-Fe(III) catalytic cycle is concerned with the tert-butoxylation, whereas a Fe(III) complex as a Lewis acid catalyzes the Friedel-Crafts alkylation.

  DOI：

  10.1021/jo102217m
• 作为产物：
  描述：

  N-甲基乙酰胺 、 溴代叔丁烷 在 羰基镁 作用下， 反应 2.0h， 以60%的产率得到N-t-butyl-N-methylacetamide
  参考文献：
  名称：

  Synthesis of N-tert-butyl amides by reaction of tert-butyl bromide with amides in the presence of manganese compounds

  摘要：

  DOI：

  10.1134/s1070428015100255

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Song Yonghong

  公开号：US20090054425A1

  公开（公告）日：2009-02-26

  Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R 1 is structure (a), (b), (c) or (d): and R a , R b , R c , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.

  化合物，特别是具有脾酪氨酸激酶（Syk）抑制活性的化合物，具有以下结构： 或其药学上可接受的盐， 其中R 1 为结构（a）、（b）、（c）或（d）： 而R a ，R b ，R c ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 和R 7 如本文所定义。涉及其制备和使用的方法，以及含有其的药物组合物，也被揭示，以及使用其来治疗由Syk和/或JAK激酶介导的疾病或疾病。
• CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR
  申请人：Lee SeoHee

  公开号：US20140031335A1

  公开（公告）日：2014-01-30

  The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.

  本发明涉及环烯基芳基衍生物及其异构体、药学上可接受的盐、水合物或溶剂合物；制备这些衍生物的方法；以及含有这些衍生物的药物组合物。本发明的化合物显示出CETP活性抑制的效果。这意味着这些化合物可以增加HDL-胆固醇并降低LDL-胆固醇。
• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180105504A1

  公开（公告）日：2018-04-19

  The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y 1 -Y 5 , R 1 , R 2 , R 3 , R 4 , and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  本发明提供了一种式I化合物：或其药学上可接受的盐，其中变量X、Y1-Y5、R1、R2、R3、R4和Het的含义如本文所述，以及含有此类化合物的组合物和使用此类化合物及组合物的方法。
• DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20170197986A1

  公开（公告）日：2017-07-13

  Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种二氢嘧啶并环衍生物作为HBV抑制剂，特别涉及一种如下式（I）所示的化合物或其药用可接受的盐。
• Reactions of carbonyl compounds in basic solutions. Part 15. The alkaline hydrolysis of N-methyl, N-phenyl and bicyclo lactams, penicillins and N-alkyl-N-methylacetamides
  作者：Keith Bowden、Keith Bromley

  DOI：10.1039/p29900002111

  日期：——

  suggest the detailed mechanisms. All the β-lactams appear to react with rate-determining addition of hydroxide anion; while the N-alkyl γ- and δ-lactams and N-alkyl-N-methylacetamides have rate-determining ring fission of the tetrahedral adduct, assisted by water-catalysis. The reactivity of penicillin in alkaline hydrolysis has been analysed by the studies of model compounds. These show that the increased

  已经在几个温度下测量了在水中或在二甲基亚砜水溶液中一系列N-甲基，N-苯基和双环内酰胺，青霉素和N-烷基-N-甲基乙酰胺的碱水解速率系数。在底物和碱中反应都是一级反应。反应性与底物的结构有关，特别是N-取代，环大小和稠环效应。反应性以及活化参数，动力学溶剂和溶剂同位素效应均被用来表明详细的机理。所有的β-内酰胺似乎都与决定加入氢氧根阴离子的反应。而N-烷基γ-和δ-内酰胺和N-烷基-N-甲基乙酰胺具有速率决定四面体加合物的环裂变，并借助水催化。青霉素在碱性水解中的反应性已通过模型化合物的研究进行了分析。这些表明，青霉素β-内酰胺环的增加的反应性是由稠合的环结构和酰氨基侧链的直接作用引起的。